Drug Discovery News Identifies Critical Bottlenecks in Cell & Gene Therapy Manufacturing: Low Viral Vector Purification Yields and Plasmid DNA Supply Shortages

July 12, 2026

Drug Discovery News USA

Overview

Drug Discovery News highlights severe bottlenecks in cell and gene therapy (CGT) manufacturing, specifically in viral vector production. Low downstream purification yields for adeno-associated virus (AAV) and lentiviral vectors, coupled with plasmid DNA supply challenges, are identified as primary inhibitors. These issues underscore the manufacturing differences between autologous and allogeneic therapies, delaying the market entry of crucial CGT products.

In Depth

Key Findings

A recent report by Drug Discovery News indicates that the cell and gene therapy (CGT) manufacturing sector is facing significant and persistent bottlenecks, primarily stemming from challenges in viral vector production. These manufacturing constraints are proving to be a major impediment to the commercialization and broader availability of advanced CGT products.

Technical / Clinical Details

The article specifically points to adeno-associated virus (AAV) and lentiviral vector manufacturing as areas under severe strain. A key issue is the persistently low downstream purification yields from viral vector production. This inefficiency leads to substantial loss of valuable vector material, directly inflating the cost of the final therapeutic product. Compounding this, the supply of high-quality plasmid DNA, essential for viral vector synthesis, is also identified as a critical bottleneck, restricting overall manufacturing capacity. The distinctions between autologous (patient-specific) and allogeneic (off-the-shelf) cell therapy manufacturing are highlighted, with each approach presenting unique scalability challenges that exacerbate these fundamental resource and process limitations.

Background & Context

Cell and gene therapies represent a revolutionary paradigm in medicine, offering curative potential for previously untreatable diseases such as various cancers and rare genetic disorders. Despite the rapid scientific advancements in drug discovery, the manufacturing infrastructure and technological maturity have struggled to keep pace. The inherent biological complexity of these products, coupled with stringent regulatory and quality control demands, makes large-scale production exceptionally difficult. Viral vectors are indispensable tools for delivering therapeutic genes into target cells, making their consistent and efficient supply crucial for the entire CGT industry’s growth. Vulnerabilities in the supply chain directly impact the ability to deliver these life-changing therapies to patients.

Strategic Significance & Outlook

Overcoming these manufacturing bottlenecks requires a concerted industry-wide effort, focusing on innovations in viral vector purification technologies, optimization of plasmid DNA production, and the development of novel manufacturing platforms. Solutions such as AI and machine learning-driven process optimization, the implementation of continuous manufacturing systems, and the utilization of standardized CDMO services are anticipated to address these issues. The industry must accelerate investment in manufacturing technology and infrastructure to ensure the sustainable growth and broader accessibility of cell and gene therapies, ultimately impacting global patient populations.

Source: https://www.drugdiscoverynews.com/scaling-the-unscalable-manufacturing-cell-gene-and-mrna-therapies-17300

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.